The shares of the German biotech company BioNTech are among the assets that you can buy or trade in online nowadays. But of course before launching into such an endeavour it is strongly recommended that you know how to complete comprehensive and pertinent analyses of this asset. For this you will need to possess sufficient economical and technical knowledge concerning the asset and this company. We offer our assistance with this by providing data and information on the BioNTech Company with details on its activities, its major competitors on the market and even its recently implemented partnerships. We will also explain how to complete a comprehensive fundamental analysis of this asset.
Firstly, regarding the activity sector in which the BioNTech Group exercises its biotechnological activities, it is important to take into account the research undertaken by this company and the progress of the different clinical trial phases of its various candidate medications.
Obtaining the authorisation for the marketing and sale from international health authorities is also of course a key factor to follow for your fundamental analysis.
Still relating to the most important data to take into consideration for this type of analysis, you should concentrate on the strategic partnerships implemented by BioNTech with other companies and notably laboratories too with the objective of obtaining financing in exchange for the commercial authorisation of these completed products.
Finally, you should also of course follow closely the activities of BioNTech’s direct competitors, these are the other biotech companies that exercise similar research activities and could therefore exert an influence to a greater or lesser degree on this company’s share price.
We shall now examine the BioNTech Group in more detail together with its activities. In fact, a comprehensive knowledge of the precise activities of this company is necessary for you to understand how it can evolve and grow and how its share price could react over the medium or long term. Here therefore is a complete presentation of this group, its activities, and major sources of revenue.
The BioNTech SE Company is a German group that exercises its activities in the biotechnological sector. More precisely this company that is based in Germany concentrates its activities in the immunotherapy segment specifically for the treatment of cancer and other serious illnesses.
This biotech company has therefore developed a wide range of products that use scientific approaches and technological platforms notably including individual product candidates based on the mRNA, chimeric antigen T cell receptors, control immunomodulators, targeted cancer antibodies and small molecules.
It should also be noted that this company offers a large range of diagnostic products and exploratory medicinal services in other therapeutic sectors such as for example infectious diseases, allergies and auto-immune illnesses.
The popularity of the BioNTech Company was recently boosted in 2020 by the implementation of a partnership with the American laboratory Pfizer for the development of the first anti-covid vaccine that received approval and that uses BioNTech’s RNA messenger technology.
The BioNTech Group currently employs around 1,300 people worldwide.
Photo credits: ©marcuskraussphotography/123RF.COM
Now that we have examined the BioNTech Company and its precise activities we will shine the spotlight on this group’s activity sectors and its major competitors on the market. In fact, other biotechs and pharmaceutical laboratories are currently in direct competition with the activities of this group and these you should know and follow their announcements, news and financial results closely.
Of course, one of the major competitors of the BioNTech Group is the Sanofi Group which is a transnational French company. Its activities include pharmaceuticals with certain prescription medications in the sectors of diabetes, rare illnesses, multiple sclerosis and oncology as well as medications for the general public health and its work in the preparation of vaccines.
This is an American biotechnological group that notably produces the Rilonacept treatment. This group from Tarrytown in the State of New York is also working on an anti-covid-19 vaccine.
This well known company is an American biotechnology company that was created in 2010 and is based in Cambridge in the state of Massachusetts. It principal objective is the creation of protein therapies founded upon a ribonucleic acid messenger otherwise known as the RNA Messenger, as with BioNTech. In fact, in 2020, Moderna itself also managed to create a vaccine for Covid-19 which was warmly received by a number of states and countries around the world and in fact obtained various approvals just after its major direct competitors in the United States and the European Union.
This pharmaceutical group is a British company that was created through the merger of the Swedish company Astra and the British laboratory Zeneca in April 1999. The group currently employs over 63,000 people around the world in various activity sectors including research, development, manufacturing, the sale of pharmaceutical products and the provision of services for medical care. The group is active in the areas of diabetes, anaesthesiology, cardiology, infectious diseases, gastroenterology, oncology, neurology and pneumology. It has also created a vaccine against the Covid-19 virus.
This is a German biopharmaceutical group which is based in Tubingen. It too is specialised in the development of therapies based on the RNA messenger otherwise known as mRNA. This group notably concentrates its activities in the development of vaccines against infectious diseases and medication for the treatment of cancer and rare diseases and illnesses. The group currently employs nearly 400 people. CureVac has signed a number of partnership agreements with other major companies and organisations such as Sanofi Pasteur, Johnson & Johnson, Eli Lilly and Company, the Coalition for Epidemic Preparedness Innovations and the International Initiative for a vaccine against AIDS. In 2020 the group also perfected a vaccine for the corona virus which was the subject of certain suspicions of poaching which created discord between the United States and Germany.
Luckily the BioNTech Group hasn’t just got adversaries on the market, it can count on a number of different significant partners such as those with which it engaged recently in strategic alliances such as the following:
Firstly, in 2020, the German biotech signed a strategic agreement with the Pfizer Company for the development of a Covid-19 vaccine. The two companies thereby collaborated on the development of an experimental vaccine, which has since been approved, which uses the RNA Messenger technology developed by BioNTech, the BNT162, with the objective of preventing infection from the new corona virus. This collaboration aimed at accelerating the development of this vaccine by benefitting from the resources of both companies. It should be remembered here that these two companies had previously signed a contract in 2018 for the development of a flu vaccine, again based on the mRNA.
Another alliance implemented recently is that between Sanofi and BioNTech. In fact, this first in the pharmaceutical sector was aimed at enabling the French laboratory, after its failure in developing a corona virus vaccine, to produce the vaccine developed by BioNTech and Pfizer. This collaboration was scheduled to begin in early summer 2021 and was aimed at compensating for the production difficulties encountered by the authorised Covid-19 vaccine manufacturers. It was foreseen that Sanofi would be responsible for the last stages in the manufacturing process with the aim of producing over 125 million doses of vaccine for the European Union.
Finally, the last partnership we shall examine that was implemented with Novartis was basically the same as that signed with Sanofi. Novartis signed an initial partnership agreement with BioNTech with the objective of packaging its mRNA vaccine in vials through its aseptic manufacturing site in Stein, Switzerland. It was agreed that, awaiting a definitive agreement, the Swiss pharmaceutical giant would start the production during the second quarter of 2021 and the first vaccine doses would be available from the third quarter.
To be able to anticipate how BioNTech's share price will evolve in the coming weeks, months or years, it is necessary to understand how this company can grow or how it can deal with the threats it may face in the future.
To carry out this type of analysis, it is of course necessary to know the main strengths and weaknesses of the company. This is what we propose to discover here in more detail:
Let's start this comparative analysis of BioNTech's strengths and weaknesses by looking at the advantages of this company, which are all arguments in favour of a rise in its share price.
Of course, the BioNTech group does not have only advantages and must also deal with certain weaknesses. It is therefore important to be aware of its weaknesses before you start buying this stock or trading it online. Here is a summary of the main weaknesses of this stock.
The last results published by the BioNTech Group are those for the 2019 financial year. For this year the group declared a turnover of 91,228,000 Euros but its net results were minus 179,172,000 Euros which represent a significant loss. This net loss was due to the fact that the company completed some significant investments that should enable it, over the long term, to generate more profits. Of course, no dividend was paid in 2020 for this financial year.
If you wish to analyse the BioNTech share price you should of course complete a technical analysis as well as a fundamental analysis. A technical analysis uses innovative and up to date charts that enable the display of trend indicators, volatility indicators and strategic thresholds for reversal or acceleration. It is of course important to correctly interpret these indicators and therefore possess a good basic knowledge in order to do so.
It is of course possible to buy BioNTech shares through certain specific financial placement products notably those specialised in the biotechnologies. It is also possible to use derived financial products that follow the growth of this underlying asset and thereby enable you to speculate online on its price.
eToro is a multi-asset platform which offers both investing in stocks and cryptoassets, as well as trading CFDs.
Please note that CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. {etoroCFDrisk}% of retail CFD accounts lose money. You should consider whether you can afford to take the high risk of losing your money.
Past performance is not an indication of future results. Trading history presented is less than 5 complete years and may not suffice as basis for investment decision.
Copy trading is a portfolio management service, provided by eToro (Europe) Ltd., which is authorised and regulated by the Cyprus Securities and Exchange Commission.
Cryptoasset investing is unregulated in some EU countries and the UK. No consumer protection. Your capital is at risk.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro.
